| 04/30/19 | HRTX | HTX-011 (NDA) | FDA decision on HTX-011 for the management of postoperative pain |
| 04/28/19 | SNYNF, SNY | Praluent (sBLA) | FDA decision to include the effect of Praluent in reducing overall risk of major adverse cardiovascular events |
| 04/28/19 | REGN | Praluent (sBLA) | FDA decision to include the effect of Praluent in reducing overall risk of major adverse cardiovascular events |
| 04/02/19 | ADMA | RI-002 (BLA resubmission) | FDA decision on RI-002 to treat primary immune deficiency disease |
| 04/01/19 | EVOK | Gimoti (NDA) | FDA decision on Gimoti for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis |
| 03/24/19 | REPH | Resubmitted IV Meloxicam (NDA) | FDA decision on resubmitted IV Meloxicam for management of moderate to severe pain |